Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Abstract: A substantially solvent-free matrix layer containing (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.

Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.

Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.

Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer layer which is remote from the skin and is based on polyisobutylenes with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the layer remote from the skin and the skin-contact layer.

Abstract: The invention relates to a method for preventing the crystallization of a pharmaceutical in a polymer film, wherein the solvent-containing coating compound, which comprises a matrix-forming polymer or polymer mixture and at least one pharmaceutical and is spread to produce the polymer film, is temporarily dried at temperatures that is at least 10° C. above the melting temperature of the pharmaceutical contained in the coating compound. The maximum temperature is thus higher than that which is required for mere drying and obviates the need for an additional, time-consuming and expensive work step.

Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.

Abstract: The invention relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer and is anchored in the backing layer by siliconization.

Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer layer which is remote from the skin and is based on polyisobutylenes with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the layer remote from the skin and the skin-contact layer.

Abstract: The invention relates to a transdermal therapeutic system which comprises a back layer that is impermeable to the active substance, and a peelable protective layer that is impermeable to the active substance and at least one matrix layer consisting of polysiloxanes and/or polysiloxane derivatives and containing micro-reservoirs. Said micro-reservoirs contain at least one ion pair from a pharmacologically active substance and an additive and either the active substance is nucleophilic and the additive is electrophilic or the active substance is electrophilic and the additive is nucleophilic.

Abstract: Transdermal therapeutic system for administering at least one active pharmaceutical ingredient which is involatile at room temperature with a daily dose not exceeding 30 mg, comprising a backing layer which is impermeable for the active ingredient and faces away from the skin, an adjoining polymer layer which is remote from the skin and is based on polyisobutylenes with a rate of application of at least 80 g/m2, an adhesive skin-contact layer which is adjacent to the polymer layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2, and a protective layer which can be detached from the skin-contact layer and is impermeable for the active ingredient.

Abstract: A multi-layer shrink film. The shrink film can exhibit a significant amount of shrink within a certain temperature range that is above the onset temperature of the film. The film can exhibit a shrinkage that is at least about 50% of the total shrink within a temperature range T1 above the onset temperature of the film. In one aspect, the shrink film comprises a core layer and skin layers disposed about opposite surfaces of the core layer, and tie layers disposed between the core and the skin layers, the skin layers individually comprising a polyester, e.g., a glycol-modified polyester, and the tie layers individually comprising an anhydride modified material.

Abstract: The invention relates to a method for preventing the crystallization of a pharmaceutical in a polymer film, wherein the solvent-containing coating compound, which comprises a matrix-forming polymer or polymer mixture and at least one pharmaceutical and is spread to produce the polymer film, is temporarily dried at temperatures that is at least 10° C. above the melting temperature of the pharmaceutical contained in the coating compound. The maximum temperature is thus higher than that which is required for mere drying and obviates the need for an additional, time-consuming and expensive work step.

Abstract: The present invention provides transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems.

Abstract: The invention relates to a method for preventing the crystallization of a pharmaceutical in a polymer film, wherein the solvent-containing coating compound, which comprises a matrix-forming polymer or polymer mixture and at least one pharmaceutical and is spread to produce the polymer film, is temporarily dried at temperatures that is at least 10° C. above the melting temperature of the pharmaceutical contained in the coating compound. The maximum temperature is thus higher than that which is required for mere drying and obviates the need for an additional, time-consuming and expensive work step.

Abstract: The invention relates to a method for preventing the crystallization of a pharmaceutical in a polymer film, wherein the solvent-containing coating compound, which comprises a matrix-forming polymer or polymer mixture and at least one pharmaceutical and is spread to produce the polymer film, is temporarily dried at temperatures that is at least 10° C. above the melting temperature of the pharmaceutical contained in the coating compound. The maximum temperature is thus higher than that which is required for mere drying and obviates the need for an additional, time-consuming and expensive work step.

Abstract: Transdermal therapeutic system with which at least one pharmaceutical active substance that is non-volatile at room temperature can be administered at a daily dose of at most 30 mg, comprising a rear surface directed away from the skin and impermeable to the active substance, an adjoining polymer layer located away from the skin and based on polyisobutylene with a coating weight of at least 80 g/m2, an adhesive skin contact layer resting on the skin-remote polymer layer and based on acrylate copolymers with a coating weight of at most 50 g/m2, and a protective layer that is impermeable to the active substance and can be peeled off from the skin contact layer.